Clinical trial
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
NCT00498797 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00498797 |
|---|---|
| Title | E3-Hormone Refractory Prostrate Cancer Taxotere Combination |
| Official title | A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC) |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Metastatic, Hormone Refractory |
| Intervention type | Drug |
| Interventions | Zactima (vandetanib), Docetaxel, Prednisolone |
| Enrollment | 86 |
| Start date | Dec 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Jul 10, 2007 |
| Last update posted | Oct 7, 2016 |
| Countries | Brazil, Germany, Hungary, South Africa, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: